BioCentury
ARTICLE | Regulation

FDA panel for mRNA-1273 highlights challenges ahead for COVID vaccine trial recruitment, retention

December 18, 2020 3:24 AM UTC

The discussion at Thursday’s FDA advisory committee meeting on a COVID-19 vaccine from Moderna and NIH highlighted the increasing difficulties of conducting trials as more vaccines become authorized and widely available. 

Out of the committee’s 21 voting members, 20 voted that the benefits of mRNA-1273 from  Moderna Inc. (NASDAQ:MRNA) outweigh its risks for use in individuals 18 years of age and older. ...